ct_gov 0.0.1

checksums.yaml

@@ -0,0 +1,7 @@
+---
+SHA1:
+  metadata.gz: e726cad0b0d02673299f96f3d350d4d27a079218
+  data.tar.gz: df9624ee898759b807acf9ec6374711db6167895
+SHA512:
+  metadata.gz: b46eb17b91d054b0b5d99ecc9312d5c144bc283d58137d45488d25812f4489c2ba0db10375ce7f9fc2681a116f1eadc92e3c6f57434748b2336ab771fbb9a0a7
+  data.tar.gz: c27d0f6f91a08049328749fc4453fae2a084ea289b8cc1aa71e0a1f107b038c04196d60d9f986c238323f792b2e8a3e643777be2774117cf49de35885598f3cf

data/.gitignore

@@ -0,0 +1,15 @@
+/.c9/
+/.bundle/
+/.yardoc
+/Gemfile.lock
+/_yardoc/
+/coverage/
+/doc/
+/pkg/
+/spec/reports/
+/tmp/
+*.bundle
+*.so
+*.o
+*.a
+mkmf.log

data/Gemfile

@@ -0,0 +1,6 @@
+source 'https://rubygems.org'
+
+gem 'rspec'
+
+# Specify your gem's dependencies in ct_gov.gemspec
+gemspec

data/LICENSE

@@ -0,0 +1,22 @@
+The MIT License (MIT)
+
+Copyright (c) 2015 Dan Carpenter
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.
+

data/README.md

@@ -0,0 +1,31 @@
+# CtGov
+
+TODO: Write a gem description
+
+## Installation
+
+Add this line to your application's Gemfile:
+
+```ruby
+gem 'ct_gov'
+```
+
+And then execute:
+
+    $ bundle
+
+Or install it yourself as:
+
+    $ gem install ct_gov
+
+## Usage
+
+TODO: Write usage instructions here
+
+## Contributing
+
+1. Fork it ( https://github.com/[my-github-username]/ct_gov/fork )
+2. Create your feature branch (`git checkout -b my-new-feature`)
+3. Commit your changes (`git commit -am 'Add some feature'`)
+4. Push to the branch (`git push origin my-new-feature`)
+5. Create a new Pull Request

data/Rakefile

@@ -0,0 +1,2 @@
+require "bundler/gem_tasks"
+

data/ct_gov.gemspec

@@ -0,0 +1,24 @@
+# coding: utf-8
+lib = File.expand_path('../lib', __FILE__)
+$LOAD_PATH.unshift(lib) unless $LOAD_PATH.include?(lib)
+require 'ct_gov/version'
+
+Gem::Specification.new do |spec|
+  spec.name          = "ct_gov"
+  spec.version       = CtGov::VERSION
+  spec.authors       = ["Dan Carpenter"]
+  spec.email         = ["daniel.carpenter01@gmail.com"]
+  spec.summary       = %q{A ruby client for the ClinicalTrials.gov api.}
+  spec.description   = %q{A ruby client for the ClinicalTrials.gov api.}
+  spec.homepage      = ""
+  spec.license       = "MIT"
+
+  spec.files         = `git ls-files -z`.split("\x0")
+  spec.executables   = spec.files.grep(%r{^bin/}) { |f| File.basename(f) }
+  spec.test_files    = spec.files.grep(%r{^(test|spec|features)/})
+  spec.require_paths = ["lib"]
+
+  spec.add_runtime_dependency "saxerator"
+  spec.add_development_dependency "bundler", "~> 1.7"
+  spec.add_development_dependency "rake", "~> 10.0"
+end

data/lib/ct_gov/clinical_trial.rb

@@ -0,0 +1,49 @@
+module CtGov
+  class ClinicalTrial
+    def initialize(raw_trial)
+      @raw_trial = raw_trial
+    end
+    
+    def nctid
+      @raw_trial['id_info']['nct_id']
+    end
+    
+    def brief_title
+      @raw_trial['brief_title']
+    end
+    
+    def official_title
+      @raw_trial['official_title']
+    end
+    
+    def brief_summary
+      @raw_trial['brief_summary']['textblock'].strip
+    end
+    
+    def detailed_description
+      @raw_trial['detailed_description']['textblock'].strip
+    end
+    
+    def eligibility_description
+      @raw_trial['eligibility']['criteria']['textblock']
+    end
+    
+    def overall_status
+      @raw_trial['overall_status']
+    end
+    
+    def publications
+      @raw_trial['reference'].map do |reference|
+        Publication.new(reference)
+      end
+    end
+    
+    def start_date
+      Date.parse(@raw_trial['start_date'])
+    end
+    
+    def study_type
+      @raw_trial['study_type']
+    end
+  end
+end

data/lib/ct_gov/publication.rb

@@ -0,0 +1,17 @@
+module CtGov
+  class Publication
+    
+    def initialize(raw_publication)
+      @raw_publication = raw_publication
+    end
+    
+    def citation
+      @raw_publication['citation']
+    end
+    
+    def pmid
+      @raw_publication['PMID']
+    end
+    
+  end
+end

data/lib/ct_gov/version.rb

@@ -0,0 +1,3 @@
+module CtGov
+  VERSION = "0.0.1"
+end

data/lib/ct_gov.rb

@@ -0,0 +1,25 @@
+require "ct_gov/version"
+require 'ct_gov/clinical_trial'
+require 'ct_gov/publication'
+
+require 'saxerator'
+
+module CtGov
+  
+  BASE_URL = 'https://www.clinicaltrials.gov'
+  BASE_OPTIONS = '?displayxml=true'
+  
+  def self.find_by_nctid(nctid)
+    uri = URI.parse("#{BASE_URL}/ct2/show/#{nctid}#{BASE_OPTIONS}")
+    http = Net::HTTP.new(uri.host, uri.port)
+    http.use_ssl = true
+    http.verify_mode = OpenSSL::SSL::VERIFY_NONE
+    
+    request = Net::HTTP::Get.new(uri.request_uri)
+    response = http.request(request)
+
+    ClinicalTrial.new(Saxerator.parser(response.body)) if response.code == "200"
+  end
+
+end
+

data/rspec/ct_gov/clinical_trial_spec.rb

@@ -0,0 +1,72 @@
+require_relative '../spec_helper'
+
+describe CtGov::ClinicalTrial do
+  
+  let(:raw_trial) { Saxerator.parser(File.read('rspec/data/sample_trial.xml')).for_tag(:clinical_study).first }
+  
+  let(:study) { described_class.new(raw_trial) }
+  
+  describe '#nctid' do
+    subject { study.nctid }
+    
+    it { expect(subject).to eq 'NCT00001372' }
+  end
+  
+  describe '#brief_title' do
+    subject { study.brief_title }
+    
+    it { expect(subject).to eq 'Study of Systemic Lupus Erythematosus' }
+  end
+  
+  describe '#official_title' do
+    subject { study.official_title }
+    
+    it { expect(subject).to eq 'Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)' }
+  end
+  
+  describe '#brief_summary' do
+    subject { study.brief_summary }
+    
+    it { expect(subject).to eq raw_trial['brief_summary']['textblock'].strip }
+  end
+  
+  describe '#detailed_description' do
+    subject { study.detailed_description }
+    
+    it { expect(subject).to eq raw_trial['detailed_description']['textblock'].strip }
+  end
+  
+  describe '#overall_status' do
+    subject { study.overall_status }
+    
+    it { expect(subject).to eq 'Recruiting' }
+  end
+  
+  describe '#start_date' do
+    subject { study.start_date }
+    
+    it { expect(subject).to eq Date.parse('1994-02-01') }
+  end
+  
+  describe '#study_type' do
+    subject { study.study_type }
+    
+    it { expect(subject).to eq 'Observational' }
+  end
+  
+  describe '#eligibility_description' do
+    subject { study.eligibility_description }
+    
+    it { expect(subject).to eq raw_trial['eligibility']['criteria']['textblock'] }
+  end
+  
+  describe '#publications' do
+    subject { study.publications }
+    
+    it { expect(subject.first).to be_a CtGov::Publication }
+    
+    it { expect(subject.count).to eq 3 }
+    
+    it { expect(subject.first.pmid).to eq '7762914' }
+  end
+end

data/rspec/ct_gov/publication_spec.rb

@@ -0,0 +1,23 @@
+require_relative '../spec_helper'
+
+describe CtGov::Publication do
+  
+  let(:raw_publication) { {
+    'citation' => "Boumpas DT, Fessler BJ, Austin HA 3rd, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med. 1995 Jul 1;123(1):42-53. Review.",
+    'PMID' => '7762914'
+  }}
+  
+  let(:publication) { CtGov::Publication.new(raw_publication) }
+  
+  describe '#citation' do
+    subject { publication.citation }
+    
+    it { expect(subject).to eq "Boumpas DT, Fessler BJ, Austin HA 3rd, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med. 1995 Jul 1;123(1):42-53. Review." }
+  end
+  
+  describe '#pmid' do
+    subject { publication.pmid }
+    
+    it { expect(subject).to eq "7762914" }
+  end
+end

data/rspec/ct_gov_spec.rb

@@ -0,0 +1,16 @@
+require_relative 'spec_helper'
+
+describe CtGov do
+  
+  describe '#find_by_nctid' do
+    
+    let(:nctid) { 'NCT01288560' }
+    
+    subject { CtGov.find_by_nctid(nctid) } 
+    
+    it 'returns a clinical trial object' do
+      expect(subject).to be_a CtGov::ClinicalTrial
+    end
+  end
+  
+end

data/rspec/data/sample_trial.xml

@@ -0,0 +1,263 @@
+<?xml version="1.0" encoding="UTF-8"?>
+<clinical_study>
+  <!-- This xml conforms to an XML Schema at:
+    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
+ and an XML DTD at:
+    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
+  <required_header>
+    <download_date>ClinicalTrials.gov processed this data on January 07, 2015</download_date>
+    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
+    <url>http://clinicaltrials.gov/show/NCT00001372</url>
+  </required_header>
+  <id_info>
+    <org_study_id>940066</org_study_id>
+    <secondary_id>94-AR-0066</secondary_id>
+    <nct_id>NCT00001372</nct_id>
+  </id_info>
+  <brief_title>Study of Systemic Lupus Erythematosus</brief_title>
+  <official_title>Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)</official_title>
+  <sponsors>
+    <lead_sponsor>
+      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
+      <agency_class>NIH</agency_class>
+    </lead_sponsor>
+  </sponsors>
+  <source>National Institutes of Health Clinical Center (CC)</source>
+  <oversight_info>
+    <authority>United States: Federal Government</authority>
+  </oversight_info>
+  <brief_summary>
+    <textblock>
+      This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their
+      relatives to learn more about how the disease develops and changes over time.  It will also
+      study genetic factors that make a person susceptible to SLE.
+
+      Patients 10 years of age and older with known or suspected SLE and their relatives may be
+      eligible for this study.  Patients will be evaluated with a medical history and physical
+      examination, blood and urine tests.  Other procedures may include:
+
+        1. Electrocardiogram
+
+        2. 24-hour urine collection
+
+        3. Imaging studies, such as chest and joint X-rays, magnetic resonance imaging (MRI)
+           scans, bone scans, and bone densitometry.
+
+        4. Questionnaire about the degree of disease activity, and survey of risk factors for
+           disease complications.
+
+        5. Apheresis   Collection of plasma (fluid portion of blood) or blood cells for analysis.
+           Whole blood is collected through a needle in an arm vein.  The blood circulates through
+           a machine that separates it into its components.  The required component (plasma or
+           cells) is removed and the rest of the blood is returned to the body through the same
+           needle or through a second needle in the other arm.
+
+        6. Skin biopsy   Removal of a small skin sample for microscopic analysis.  An area of skin
+           is numbed with an anesthetic and a small circular portion (about 1/4 inch in diameter)
+           is removed, using a sharp cookie cutter-type instrument.
+
+        7. Kidney, bone marrow or other organ  biopsy   Removal of a small sample of organ tissue.
+            These biopsies are done only if they can provide information useful in better
+           understanding the disease or making treatment decisions.
+
+        8. Genetic studies   Collection of a blood sample for gene testing.
+
+      Patients will be followed at least once a year with a brief history and physical examination
+      and routine blood and urine tests.  Some patients may be seen more often.  Treatment
+      recommendations will be offered to patients' physicians, and patients who are eligible for
+      other research treatment studies will be invited to enroll.
+
+      Participating relatives of patients will fill out a brief medical history questionnaire and
+      provide a DNA sample (either a blood sample or tissue swab from the inside of the cheek) for
+      genetic testing.
+    </textblock>
+  </brief_summary>
+  <detailed_description>
+    <textblock>
+      This research protocol will evaluate subjects with systemic lupus erythematosus (SLE) and
+      their relatives to study the pathogenesis and natural history of the disease and the
+      mechanisms leading to enhanced organ damage.  Patients will be evaluated by a history and
+      physical examination and routine laboratory studies will be obtained as needed to assess
+      disease activity or complications of the disease and to monitor for drug-related toxicities.
+       Blood, skin or urine specimens may be requested for research purposes, including genetic
+      studies.  In addition, a subset of these patients will undergo several tests to understand
+      the pathogenic changes affecting their blood vessels. Patients who are eligible for other
+      research protocols will be offered the opportunity to participate in these studies by signed
+      informed consent.  Any medical care recommended or provided to the patient will be
+      consistent with routine standards of practice and provided in consultation with the patient
+       s referring physician.  Blood and urine samples and cardiovascular testing will also be
+      collected or applied to from healthy volunteers for research purposes and to support the
+      identification and validation of new biomarker candidates.
+    </textblock>
+  </detailed_description>
+  <overall_status>Recruiting</overall_status>
+  <start_date>February 1994</start_date>
+  <phase>N/A</phase>
+  <study_type>Observational</study_type>
+  <study_design>N/A</study_design>
+  <enrollment type="Anticipated">100000</enrollment>
+  <condition>Systemic Lupus Erythematosus</condition>
+  <eligibility>
+    <criteria>
+      <textblock>
+        -  INCLUSION CRITERIA:
+
+        Patients with known or suspected SLE will be evaluated in either the outpatient or
+        inpatient research ward of the Clinical Center as indicated.  Patients will not be
+        selected based on age, race or gender.  However, due to the nature of the disease, the
+        patient population will not be expected to be evenly distributed, since SLE is
+        predominantly a disease of young females, with increased prevalence in select racial
+        groups, particularly African Americans and Hispanics. First and second-degree relatives of
+        the patient may be recruited in the study for genetic analysis.  We will ask for the
+        patient   s permission to contact his/her relatives, as described in details in Section
+        IV.H.
+
+          -  SLE or suspected SLE established by ACR criteria
+
+          -  Ability to give informed consent
+
+          -  Adult and minor relatives (first and second degree) of individuals Included in IV-G
+             (only for genetic studies)
+
+          -  Ability of the patient or minor relative   s parents to give informed consent
+
+        EXCLUSION CRITERIA:
+
+          -  Concomitant medical problems which would confound the interpretation of studies
+             gathered by this protocol. Included in this is the presence of HIV in the blood if it
+             interferes with interpretation of some lupus studies.
+
+          -  Concomitant medical, surgical or other conditions for which inadequate facilities are
+             available to support their care at NIH
+
+        Criteria for Healthy Control Subjects:
+
+        INCLUSION CRITERIA:
+
+          -  Age 18 years with no upper age limit.
+
+          -  For vascular studies healthy control subjects will be age- and gender-matched.
+
+          -  For genetic studies only: Minor relatives (first and second degree) of SLE subjects
+             Included in section IV-G.
+
+          -  Ability to give informed consent or minor relative   s parents to give informed
+             consent (for genetic studies only).
+
+        EXCLUSION CRITERIA:
+
+        -Any concomitant medical problems or are taking medications which would confound the
+        interpretation of studies they are considered for
+
+        Exclusion Criteria for vascular studies only, for SLE and healthy controls:
+
+          -  Subjects with a contraindication to MRI scanning will not receive the optional
+             PET/MRI. These contraindications include subjects with the following devices:
+
+               -  Central nervous system aneurysm clips
+
+               -  Implanted neural stimulator
+
+               -  Implanted cardiac pacemaker or defibrillator
+
+               -  Cochlear implant
+
+               -  Ocular foreign body (e.g. metal shavings)
+
+               -  Implanted Insulin pump
+
+               -  Metal shrapnel or bullet
+
+          -  Subjects with a BMI &gt; 40 will also not receive the PET MRI.
+
+          -  Subjects with renal excretory dysfunction, estimated glomerular filtration rate &lt;  60
+             mL/min/1.73m(2) body surface area according to the Modification of Diet in Renal
+             Disease criteria, will not receive the cardiac CT angiography, or gadolinium contrast
+             agent during the PET/MRI.
+
+          -  Pregnant or lactating women will be excluded from vascular studies.
+
+          -  Healthy controls with known history of coronary artery disease, peripheral vascular
+             disease or atherosclerosis.
+
+          -  Individuals younger than 18 years old will be excluded given the radiation exposure
+             as well as the lack of proper validation for the proposed vascular function studies.
+      </textblock>
+    </criteria>
+    <gender>Both</gender>
+    <minimum_age>N/A</minimum_age>
+    <maximum_age>N/A</maximum_age>
+    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
+  </eligibility>
+  <overall_official>
+    <last_name>Sarfaraz A Hasni, M.D.</last_name>
+    <role>Principal Investigator</role>
+    <affiliation>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</affiliation>
+  </overall_official>
+  <overall_contact>
+    <last_name>Elizabeth Joyal, R.N.</last_name>
+    <phone>(301) 435-4489</phone>
+    <email>ejoyal@mail.cc.nih.gov</email>
+  </overall_contact>
+  <overall_contact_backup>
+    <last_name>Sarfaraz A Hasni, M.D.</last_name>
+    <phone>(301) 451-1599</phone>
+    <email>hasnisa@mail.nih.gov</email>
+  </overall_contact_backup>
+  <location>
+    <facility>
+      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
+      <address>
+        <city>Bethesda</city>
+        <state>Maryland</state>
+        <zip>20892</zip>
+        <country>United States</country>
+      </address>
+    </facility>
+    <status>Recruiting</status>
+    <contact>
+      <last_name>For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)</last_name>
+      <phone>800-411-1222</phone>
+      <phone_ext>TTY8664111010</phone_ext>
+      <email>prpl@mail.cc.nih.gov</email>
+    </contact>
+  </location>
+  <location_countries>
+    <country>United States</country>
+  </location_countries>
+  <link>
+    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1994-AR-0066.html</url>
+    <description>NIH Clinical Center Detailed Web Page</description>
+  </link>
+  <reference>
+    <citation>Boumpas DT, Fessler BJ, Austin HA 3rd, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med. 1995 Jul 1;123(1):42-53. Review.</citation>
+    <PMID>7762914</PMID>
+  </reference>
+  <reference>
+    <citation>Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994 Apr 1;152(7):3685-92.</citation>
+    <PMID>8144943</PMID>
+  </reference>
+  <reference>
+    <citation>Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994 Apr 1;179(4):1317-30.</citation>
+    <PMID>7511686</PMID>
+  </reference>
+  <verification_date>August 2014</verification_date>
+  <lastchanged_date>November 11, 2014</lastchanged_date>
+  <firstreceived_date>November 3, 1999</firstreceived_date>
+  <responsible_party>
+    <responsible_party_type>Sponsor</responsible_party_type>
+  </responsible_party>
+  <keyword>Systemic Lupus Erythematosus</keyword>
+  <keyword>Natural History</keyword>
+  <keyword>Lupus Nephritis</keyword>
+  <keyword>Lupus</keyword>
+  <keyword>Systemic Lupus</keyword>
+  <keyword>SLE</keyword>
+  <is_fda_regulated>No</is_fda_regulated>
+  <has_expanded_access>No</has_expanded_access>
+  <condition_browse>
+    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
+    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
+  </condition_browse>
+  <!-- Results have not yet been posted for this study                                -->
+</clinical_study>

data/rspec/spec_helper.rb

@@ -0,0 +1,4 @@
+require 'bundler/setup'
+Bundler.setup
+
+require 'ct_gov'

metadata

@@ -0,0 +1,101 @@
+--- !ruby/object:Gem::Specification
+name: ct_gov
+version: !ruby/object:Gem::Version
+  version: 0.0.1
+platform: ruby
+authors:
+- Dan Carpenter
+autorequire: 
+bindir: bin
+cert_chain: []
+date: 2015-01-09 00:00:00.000000000 Z
+dependencies:
+- !ruby/object:Gem::Dependency
+  name: saxerator
+  requirement: !ruby/object:Gem::Requirement
+    requirements:
+    - - ">="
+      - !ruby/object:Gem::Version
+        version: '0'
+  type: :runtime
+  prerelease: false
+  version_requirements: !ruby/object:Gem::Requirement
+    requirements:
+    - - ">="
+      - !ruby/object:Gem::Version
+        version: '0'
+- !ruby/object:Gem::Dependency
+  name: bundler
+  requirement: !ruby/object:Gem::Requirement
+    requirements:
+    - - "~>"
+      - !ruby/object:Gem::Version
+        version: '1.7'
+  type: :development
+  prerelease: false
+  version_requirements: !ruby/object:Gem::Requirement
+    requirements:
+    - - "~>"
+      - !ruby/object:Gem::Version
+        version: '1.7'
+- !ruby/object:Gem::Dependency
+  name: rake
+  requirement: !ruby/object:Gem::Requirement
+    requirements:
+    - - "~>"
+      - !ruby/object:Gem::Version
+        version: '10.0'
+  type: :development
+  prerelease: false
+  version_requirements: !ruby/object:Gem::Requirement
+    requirements:
+    - - "~>"
+      - !ruby/object:Gem::Version
+        version: '10.0'
+description: A ruby client for the ClinicalTrials.gov api.
+email:
+- daniel.carpenter01@gmail.com
+executables: []
+extensions: []
+extra_rdoc_files: []
+files:
+- ".gitignore"
+- Gemfile
+- LICENSE
+- README.md
+- Rakefile
+- ct_gov.gemspec
+- lib/ct_gov.rb
+- lib/ct_gov/clinical_trial.rb
+- lib/ct_gov/publication.rb
+- lib/ct_gov/version.rb
+- rspec/ct_gov/clinical_trial_spec.rb
+- rspec/ct_gov/publication_spec.rb
+- rspec/ct_gov_spec.rb
+- rspec/data/sample_trial.xml
+- rspec/spec_helper.rb
+homepage: ''
+licenses:
+- MIT
+metadata: {}
+post_install_message: 
+rdoc_options: []
+require_paths:
+- lib
+required_ruby_version: !ruby/object:Gem::Requirement
+  requirements:
+  - - ">="
+    - !ruby/object:Gem::Version
+      version: '0'
+required_rubygems_version: !ruby/object:Gem::Requirement
+  requirements:
+  - - ">="
+    - !ruby/object:Gem::Version
+      version: '0'
+requirements: []
+rubyforge_project: 
+rubygems_version: 2.4.2
+signing_key: 
+specification_version: 4
+summary: A ruby client for the ClinicalTrials.gov api.
+test_files: []